News | June 03, 2021
Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
This is the ninth Covid-19 vaccine approved in India
Sputnik M is a new member of the Sputnik vaccines family
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The first batch will be shipped to the Gamaleya Center for the quality control
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
